Ronald Reagan Presidential Library Digital Library Collections

This is a PDF of a folder from our textual collections.

Collection: Turner, Carlton E.: Files Folder Title: DuPont Chemical, Wilmington, Delaware 09/10/1982

Box: 24

To see more digitized collections visit: https://www.reaganlibrary.gov/archives/digitized-textual-material

To see all Ronald Reagan Presidential Library Inventories, visit: https://www.reaganlibrary.gov/archives/white-house-inventories

Contact a reference archivist at: reagan.library@nara.gov

Citation Guidelines: https://reaganlibrary.gov/archives/research-support/citation-guide

National Archives Catalogue: https://catalog.archives.gov/

Last Updated: 8/19/2025

WITHDRAWAL SHEET

Ronald Reagan Library

Collection Name .MACDONALD, DONALD IAN (MAC): FILES

Turner, Carlton E. Files

Withdrawer

KDC

6/13/2011

File Folder

DUPONT CHEMICAL WILMINGTION, DEL. - 9/10/82

FOIA

F06-0059/02

Box Number

19057 24

POTTER

OC D	ос Туре	Document Description	No of Pages	Doc Date R	estrictions
	RAVEL OUCHER		5	9/30/1982	В6
Α	TRAVEL AUTHORIZA TON		1	ND	B6

Freedom of Information Act - [5 U.S.C. 552(b)]

B-1 National security classified information [(b)(1) of the FOIA]

B-2 Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]

B-3 Release would violate a Federal statute [(b)(3) of the FOIA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

B-4 Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]

B-6 Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]

B-7 Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]

B-8 Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA] B-9 Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

1 Slide show an DuPont (Glacomd - Pot - change This fort-1 Slide - Pot-Coldine - heroin @ 1 /2 Lago/ proscription drugs. 1 82 NDCC 79 Billian Schedule I programs. 3. ARCOS - Showe DEA ARCOS -> DADS 4. 75tates multi-preseription requirement. Calif - 1940 started Cost 1981- 600,000 4% of Cases oransins N. 4 Cost 1981 \$500,000 2 covicta 5. ARCOS Intelligences New Hampshine. Wisconsa, Massour; 8 Physicans writing waterouty g scrips 2 courted Now Sales down 6. Counil & State Governments to USE ARCOS to identify progons, 7. Cost - Drugs, Lost scrips, Errors

& Boards Will not take strong Actions

The Dupont Company: people met on 9/10

i) John F. Mcallister
Director, Envir & Energy Division
PA Dept

2) Paul H. Wychedr & Consultant PA Dept

3) Hazen L. Richardson - "Rich"
Gen Man
Bio Chemicals Dept.

H) Richard Hamilton "Pick"

PA Representatives

> did arrangements

5) Dr. Bruce W. & Karrh, MD Director Medical Division, Employee Rel Dept

6) Van H. Leichliter VP & Gen Counsel Endo Laboratory Inc

DUPONT COMPANY

SI Wilmington, DE

19898

THE WHITE HOUSE

WASHINGTON

THE DUPONT COMPANY
Wilmington, Deleware
September 9, 1982

NOTE: Steve Jacobs used to work for Dupont and will be your guide.

8:25 am - Car leaves the ramp for Union Station

** You will need to purchase the tickets at the Station

9:00 am - Metroliner departs Washington enroute Wilmington

10:20 am - Arrive Wilmington

Steve will direct you to the offices.

CONTACT:

Dick Hamilton - 302/773-3239

I suggest you get an open return, however, there is a 3:00 metroliner which would get you back in D.C. at 4:45.

CALL THE OFFICE WHEN YOU KNOW WHEN YOU WILL BE ARRIVING IN D.C. AND I WILL ARRANGE FOR A CAR TO MEET YOU.

Patrick A. TURNER Vice-President

900 -> 10 29 *282

307 -> 445 #115

FEATURES

Bob Dulon

DuPont says message is flawed and dangerous

'Disease concept' a drug debate smoke screen

WASHINGTON - Robert DuPont has no doubt; applying the "disease concept" to every aspect of the substance abuse problem is wrong and a dangerous game played, unfortunately, by some well-meaning people in the treatment field.

And there are those he does not consider so well-meaning — they are trying to use the issue as a smoke screen to get some illegal drug legalized.

Nor does Dr DuPont have much time for those who advocate "responsible use" of drugs, especially as it can be a lure to young people to experiment.

Dr DuPont, president of the American Council for Drug Education, former director of the United States National Institute on Drug Abuse (NIDA), practising psychiatrist, and oft-quoted expert for the press. is certainly seen as expressing the views of those who can influence policies.

He is no stranger to controversy - in 1977, while still director of the NIDA, he stirred the wrath of some scientists by suggesting that their fight to decriminalize possession of small amounts of marijuana was giving the false message that the drug was innocuous (The Journal, Aug, 1977). A supporter of the parents' movement from the beginning, he has insisted the organizations must tackle the problems of adolescent drinking with vigor equal to that used to tackle teenage marijuana use.

Dr DuPont has put some of his ideas in his just-published book, Gateway Drugs.

In a recent conversation here with The Jounral's contributing editor Harvey Mc-Connell, Dr Du-Pont tackled the questions of "disease concept" and "responsible use," and why he thinks the ideas are misleading.



McConnell

Dr DuPont believes "the disease concept is a very powerful, and really a very helpful idea in the context of the treatment of alcoholism. What it says to the alcoholic is: 'You have an incurable, progressive, and potentially fatal disease, and the only way you are going to be able to survive is to not drink.

"That is a powerful and good message.

"But where the disease concept is not only flawed, but dangerous, is when we talk about it in the context of social policy on the one hand and prevention on the oth-

er. This makes the assumption there are two kinds of drug users: one is sick and one is well; one is diseased and the other is healthy.

"This can serve as a beacon attracting in people who are going to become addicted. Thus, you say there is a disease concept, or addictionologic concept; there are some people who can handle it and some who cannot.

"But there is no way a 16-year-old is to know whether or not he can handle it, except to try it. Nobody can tell him."

Dr DuPont says he has heard the disease concept and the language of addictionology applied by some people to the use of marijuana. They reason,

he says, that "some people are 'pot heads' and have problems, but one does not really want to deal with them because they are sick. On the other hand, there are lots of other people using marijuana, it is an innocent, recreational activity, and there is no reason for anyone else - especially the law or health officials - to be concerned."

When it comes to treatment, Dr DuPont continues, "and I am asked if I believe in the disease concept, I say 'yes.' I think many people using the disease concept, or addictionologic concept, have a sincere interest and concern for drug-dependent and alcohol-dependent people. I have no quarrel with that.

"But when these people step out of the treatment field and go into the social policy and prevention fields. I have big problems with them, and I think they are dan-

"In addition, I think a lot of other people have jumped on this particular bandwagon as a kind of stalking horse for the legalization of drugs. They are the same group who are for the medical use of illicit drugs; the same group who want decriminalization of some drug use.

"Basically, they have been frustrated in their primary objective - legalization and what they are now looking around for is an alternative which will give them at least half a loaf."

中 全部 一层海 東南

All in all, he believes that trying to apply the disease concept to the prevention field and social policy "is such an awful argument, it won't go anywhere."

Another bête noir of Dr DuPont's is the "responsible use" concept. "Lots of terms are used to describe it: harmless drug use, controlled drug use, recreational drug use, moderate drug use, occasional drug use, adult drug use. What it means is the use of pleasure-producing chemicals. 'Responsible use' is a rhetorical blanket which gets tossed over a lot of very messy stuff that a lot of people don't want to look

DuPont: bandwagon Drug users are 'again divided under this guise into the sick and the well; the sick probably need some education and treatment, while the well drug users are doing fine and one should respect their personal decision on how they run their lives.

> "The trouble is that everybody starts out to become a social drug user. Nobody starts out to become an addict. So, by holding out the image of a target where you can have a free lunch with chemical highs, which is what the 'responsible use' thing says, this gives incentive and encouragement to entering the drug dependency syndrome that leads into addiction.

"Thus 'responsible use' is like a pump, pumping people into dependence."

As to why people use drugs, Dr DuPont believes the answer is simple: "People use drugs because they like the feelings that drugs produce. That's all.

"You can use if you are rich or poor, old or young, hot or cold, happy or sad. But it all comes down to a simple fact: drugs work. They take over the pleasure centre of the body and produce feelings that the users like. It isn't any more complicated. You don't have to look at any other underlying causes."

The siren song of "responsible use" leads many teenagers into using drugs and thinking they know what they are doing. "The reality is that the pool of people called responsible drug users are only one step away from the rest with problems.

They are not a separate population, and that is what people who talk about responsible use don't want to know.

In his book, Gateway Drugs, he concentrated on alcohol, marijuana, and cocaine. "I see them as the gateways into the drug dependence syndrome for two reasons: because people misperceive them to be harmless, and because people misperceive them to be easily controlled."

Alcohol is the gateway to the use of intoxicating chemicals, marijuana the gateway to the use of other illegal drugs, and cocaine the gateway into intensified drug use. They are progressive - alcohol to marijuana to cocaine - and through all three, "a whole smorgasbord of drugs" is spread out, he says.

The past two decades have seen the use of alcohol by teenagers change dramatically. Some use by some teenagers was always present, but now alcohol is almost universally used. Yet, he thinks, the tide can be pushed back.

"We might be going back to the days when drinking by teenagers was the exception rather than the rule, and when drinking does occur, it is quite moderate, which does not happen now.

And it is high school students who convince Dr DuPont that he could be right. "I speak to a lot of high school groups and I'm getting a very sympathetic hearing. They listen. It is really interesting - their changed attitudes.

"They are much more receptive to what used to be thought of as a hard-line about drugs and alcohol. One reason they are doing this is because they have seen what has happened to the previous generation, what I call the drug-dependent generation, those caught up in drugs in the late 1960s and early and mid 1970s.

"The kids look at them as an abberation. as pathetic.'

Many in this generation, he says, have been devastated by alcohol and other drugs and have not been able to take their places in society. Quite a number are still dependent on their families, are unable to set themselves into a career, unable to establish themselves in marriage.

Dr DuPont: "Many of the young people today are sobered by what they see around them. It is interesting. Many of the experts who have what I consider pro-drug values really think about kids as the way kids were 10 years ago. They are very shocked at the way kids are today, and the very different attitudes they have.'

Dupont

January 9, 1985 THE WHITE HOUSE

WASHINGTON

Dear Kathleen:

Thank you so very much for the photo of me and Dr. Benny Prim. It certainly reminded me of the press conference for the launch of Trexon.

Enclosed is a xeroxed copy of a letter I received from a lady in Miami Beach, Florida. I thought you would find it of interest.

Thank you for all of the work Dupont is doing to reduce drug abuse. We too, look forward to seeing the activity books. Best regards,

Sincerely,

Carlton/E. Turner, Ph.D.
Special Assistant to the President
for Drug Abuse Policy

Kathleen D. MacClean M.C. Specialist, Dupont Company Marketing Communications Department Wilmington, Delaware 19898



E. I. DU PONT DE NEMOURS & CO. (INC.) MARKETING COMMUNICATIONS DEPARTMENT WILMINGTON, DELAWARE 19898

December 14, 1984

Carlton E. Turner, Ph.D.
Special Assistant to the President
for Drug Abuse Policy
Drug Abuse Policy Office
The White House
Washington, D.C.

Dear Dr. Turner:

It was so nice to have met you in New York recently and, again, I would like to thank you for participating in the press conference for the launch of TREXAN It meant a great deal to all of us.

I came across the enclosed photo of you and Beny Primm and thought you might enjoy a copy. I'm sending one to Beny as well.

Have a lovely holiday season. I look forward to our work on the drug abuse "activities book" with you and Steve Jacobs.

Best personal regards,

Kathleen D. MacLean

Marketing Communications Specialist

KDM/bg

Enclosure

ASSIGNMENT
mo.
TO: CT SL JB
DL JK SJ
DW SD BB
Xerox Make a File
#Name
☐ File ☐ Look Into
☐ Draft ☐ Contact
DETAILS/OTHER:
I meed your
Expenses (including
metroliner reciept)
Rogular
Breakfit - 2.75
Levery N. C
- Travel

September 15, 1982

I met with the following individuals of the DU PONT Company during my visit there, September 10, 1982.

John F. McAllister Director, Environment and Energy Division Public Affairs Department

Paul H. Wyche, Jr. Consultant Public Affairs Department

Hazen "Rich" L. Richardson General Manager BioChemical Department

Richard "Dick" Hamilton Public Affairs Representative

Dr. Bruce W. Karrh, M.D. Director, Medical Division Employee Relations Department

Van H. Leichliter Vice President and Genral Counsel Endo Laboratory, Inc.

ADDRESS:

DU PONT COMPANY Wilmington, DE 19898



E. I. DU PONT DE NEMOURS & COMPANY

WILMINGTON, DELAWARE 19898

PUBLIC AFFAIRS DEPARTMENT

20 SEP 1982

September 14, 1982

Dr. Carlton E. Turner
Director, Drug Abuse Policy Office
Office of Policy Development
The White House
Washington, D.C. 20500

Dear Dr. Turner:

I want to thank you and Steve for taking the time to visit Du Pont. We were all very impressed with your program.

We look forward to working with you in the future. After we have had some time to look at what Steve puts together for us in the way of a physician/pharmacist patient education program, I'll let you know to what extent we will be involved. You will be hearing from Van Leichliter regarding the DEA meeting you offered to arrange.

Thanks again for your time.

Sincerely

Richard B. Hamilton

RBH:drc

WITHDRAWAL SHEET

Ronald Reagan Library

Collection Name	Withdrawer
MACDONALD, DONALD IAN (MAC): FILES- Turner, Carlton E. Files	KDC 6/13/2011
File Folder	FOIA
DUPONT CHEMICAL WILMINGTION, DEL 9/10/82	F06-0059/02 POTTER
Box Number 19057- 24	12
DOC Document Type NO Document Description	No of Doc Date Restric- pages tions

9/30/1982 B6

TRAVEL VOUCHER

1

Freedom of Information Act - [5 U.S.C. 552(b)]

B-1 National security classified information [(b)(1) of the FOIA]

B-2 Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]

B-3 Release would violate a Federal statute [(b)(3) of the FOIA]

B-4 Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]

B-6 Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]

B-7 Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]

B-8 Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]

B-9 Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

THE WHITE HOUSE

WASHINGTON

August 30, 1982

MEMORANDUM FOR ROGER PORTER

FROM:

CARLTON TURNER

SUBJECT:

Travel Request - The Dupont Company

Through the efforts of Steve Jacobs, Customs, we have created an enthusiastic interest on the part of the Dupont Company in joining the battle against drug abuse.

An integral part of our overall drug program is in education and prevention efforts. The success or failure is partially contingent upon participation by the private sector. The Dupont Company is very interested in helping the cause and would like to contribute in a <u>significant</u> way, however, they have asked for direction.

I have tentatively scheduled a meeting in their corporate offices (Wilmington, Deleware) for Friday, September 10 with their designated executives. This meeting would be for the purpose of discussing specific ways in which the company could get involved, in a big way, keeping in mind the image of the company itself, the image they want to project and the goals they have set for this endeavor.

I recommend approval of this travel. The cost would be approximately \$88, including travel, taxis and meals. Attached is a travel authorization to cover these anticipated expenses. If you have any questions please let me know.

WITHDRAWAL SHEET

Ronald Reagan Library

Collection Name MACDONALD DONALD IAN (MAC): FILES:	Withdrawer KDC 6/13/2011
MACDONALD, DONALD IAN (MAC): FILES Tumer, Carlton E.: Files	1100 0/10/2011
File Folder	FOIA
DUPONT CHEMICAL WILMINGTION, DEL 9/10/82	F06-0059/02
	POTTER
Box Number	
19057. 24	12
DOC Document Type	No of Doc Date Restric-
NO Document Description	pages tions

1

ND

B6

Freedom of Information Act - [5 U.S.C. 552(b)]

TRAVEL AUTHORIZATION


2

- B-1 National security classified information [(b)(1) of the FOIA]
- B-2 Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- B-3 Release would violate a Federal statute [(b)(3) of the FOIA]
- B-4 Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- B-6 Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- B-7 Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- B-8 Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- B-9 Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]
- C. Closed in accordance with restrictions contained in donor's deed of gift.

(Name, office symbo				
building, Agency/Po	l, room number,		Initials	Date
	,00	>		
	16 am			
	// *			
				-
•				
Action	File	Note	and Retu	rn
Approval	For Clearance	+	Conversat	
As Requested	For Correction	Prep	are Reply	
Circulate	For Your Information	See		
Comment	Investigate	Sign	ature	
Coordination REMARKS	Justify		-	
	302/77			
J. Pren	P.A D Dolor Will	ept +	Co.	107
DO NOT use this form	P.A Dolor Dolor Will as a RECORD of approvals,	lept + mi les	Co.	18:
DO NOT use this form	as a RECORD of approvals, clearances, and similar action	lept + mi Leconcur	Co.	107 18!
A. C.	as a RECORD of approvals, clearances, and similar action	lept + mi Leconcur	Co-	107 189 extry
A. C.	as a RECORD of approvals, clearances, and similar action	Legional Ro	Co-	107 18!
A. C.	as a RECORD of approvals, clearances, and similar action bol, Agency/Post)	concurris Ro	Co- ngt frances, do om No.— one No.	18 evily lisposals
ROM: (Name, org. sym	as a RECORD of approvals, clearances, and similar action bol, Agency/Post) OPTIONAL Prescribed	concurris Ro	Co_ rences, do one No.—	8 extra 8

Dupont Very inter comm Want. sig. way Know CT set mtg @ HQ @
Wilmingten

4 CT 4 aliscuss 00/5)



8/25 Travel to wilming fon, Del.

900 Metro liner 1000

\$19.20@ way

about @ hr.

38.40